The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and these patents are valid through 2025, the company said in a filing to the BSE today.
Suven CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medical need with huge market potential globally."
These new chemical entities are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia, the filing said.
With these new patents, the company has a total of 14 granted patents from Canada, 12 from China and 17 from India.
Products out of these inventions may be out-licensed at various phases of clinical development, the company said.